

COVID 19 TEST KIT

CORONA VIRUS RAPID TEST KIT

Widely used in Hospitals, Hygiene, Medical Lab, Household, Commercial Buildings, Personal Care



CERTIFICATION: CE, FDA, ISO Certificate

QUANTITY: Minimum 100,000 pcs

TERMS:

Video evidence will be provided

50% T/T Advance along with Purchase Order 50% T/T balance on invoice before shipment Rapid Test Kit, With all certificates, Instant Covid-19 Detection through blood analysis, used widely by professionals

SPECS:

IgG/ IgM Rapid Test through Whole Blood/ Serum/ Plasma Fast results (2-10 mins) All necessary reagents provided No additional equipment needed

PRICE:

\$ TBC FOB per Set. 1 Million Plus Quantities 500.000 1 Million + \$1. Quantities below 500.000 + \$4

SHIPMENT:

FOB China CIF: Upon Request.

REMARKS:

- Shipment within 3 days of advance payment
- Air shipment 3-5 days
- First come first serve basis

| | | SOD | | |
|--|--|---------------|--|---|
| CERTIFI | CATE | | | |
| No. QS6 058008 0029 | Rev. 00 | | (2) t | PAL STORE PL |
| Regulatory Requirements: | Australia Therapeutic Goods (Medical Devices) Regulations 2002 | | | - Marina M |
| | - Schedule 3, Part 1 | | | |
| | Brazil - RDC ANVISA n. 16/2013 - RDC ANVISA n. 23/2012 | | | |
| | - RDC ANVISA n. 67/2009 Canada | | | |
| <u></u> | - Medical Device Regulations SOR/98-282, Part 1 United States | | | |
| | - 21 CFR Part 803 - 21 CFR Part 806 | S | ARS-CoV-2 A | Intibody Test |
| | - 21 CFR Part 807 - 21 CFR Part 820 | | ateral flow metho | |
| Facility(ies): | GUANGZHOU WONDFO BIOTECH CO., LTD. No. 8 Lizhishan Road, Science City, Luogang District, 5106 | | dieral flow merno | u) |
| | Guangzhou, PEOPLE'S REPUBLIC OF CHINA | | | |
| Facility Scopes: | Design and Development, Production, Service, Installation, | 1 | | Wandlo' |
| | and Distribution of In-Vitro Diagnostics for the Detection of Fertility, Pregnancy, Infectious Diseases, Drugs of Abuse, | · · · · · | As an auxiliary and supplemen further diagnosis to the patie | |
| | Tumor Markers, Cardiac Markers, Renal Injury Markers, Autoimmune Diseases, Infection and Inflammation Markers and Related Instruments, Sperm Concentration Test, | | result in PCR. Easy to use, instant result in 15 i | minutes |
| | and Related Instruments, Sperm Concentration Test, Fluorescence Immunoassay System, Blood Glucose Monitoring System | | Cast in cast in signification (esolit in 15) | |
| | Monitoring System DUNS No: 53-014-8055 | | ccording to the Novel Coronavin | is Pneumonia Diagnosis and Treatment Plan tional health committe, serology testing can b |
| | | | iagnostic method of COVID-19 in | ifection. |
| | | | • | |
| | | Table 1 | | IgG Antibodies can be detected a week after infection, with sligh |
| | | Concentration | CM CM | between individuals. |
| Page 2 of 2 Date of Issue: 2019-02-18 | ul 🗸 | S | Λ_{2} | Negative result indicates r infection at a very early sta |
| | Rhar | | | few days). |
| TÜV SÜD Amarica Inc. • 10 Center | (Arie Henkin) Manager, Cerbitication Body MHS mial Drive Ste 207 • Peabody, MA 01960 USA • www.tuvsud.com | | | Positive result indicates an coronavirus. |
| | | τυν® | First infection Second infect ler information | ion |
| | | | Product name Packir | g size Sample type Storage condition |
| | aration of Conformity | E | SARS-CoV-2Antibody 2/ st (Lateral flow method) 2/ between controls and the set of the set between controls and the set of the set | serom ana prasma |
| in accord | ration of Conformity ance with Directive 98/79/EC | E | SARS-CoV-2Antibody 20 st (Lateral flow method) 20 | serum and plasma |
| | and a second data and the second s | E | ARS-CoV-2Antibody t (Lateral flow method) 20 Control flow method) Control flow methods Control flow method | serum and plasma 2 C=30 C |
| in accord | and a second data and the second s | E | CERTIFIC | CATE |
| in accord | and a second data and the second s | E | CERTIFIC | CATE |
| in accord | ance with Directive 98/79/EC | E | CERTIFIC | CATE Rev. 00 |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes | ance with Directive 98/79/EC Catalogue number t Device K460216D | | Certificate Holder: | CATE Rev. 00 CUANGZHOU WONDFO BIOTECH CO., LTD. No. 8 Lizhishan Road, Science City |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes | ance with Directive 98/79/EC | | Certificate Holder: | CATE Rev. 00 GUANGZHOU WONDFO BIOTECH Co., LTD. No. 8 Lizhishan Road, Science City Lucgang District 510683 Guangzhou |
| in accord nufacturer: <u>Product/s</u> 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi | ance with Directive 98/79/EC Catalogue number t Device K460216D | | ARS-CoV-2Antibody tradeoutletownethod) Control and the second | CATE Rev. 00 GUANGZHOU WONDFO BIOTECH Co., LTD. No. 8 Lizhishan Road, Science City Lucgang District 510683 Guangzhou |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi formity assessment route: A | ance with Directive 98/79/EC Catalogue number t Device K460216D ces except Annex II and self-testing devices) nnex III,except Point 6,of Directive | | ARS-CoV-2Antibody tradeoutletownethod) Control and the second | CATE Rev. 00 GUANGZHOU WONDFO BIOTECH Co., LTD. No. 8 Lizhishan Road, Science City Lucgang District 510683 Guangzhou |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISC SO 14971:2012 ;EN ISO 1: | ance with Directive 98/79/EC Catalogue number t Device K460216D ces except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 8612:2002;EN ISO 17511:2003; | | ARS-CoV-2Antibody tradeoutletownethod) Control and the second | Serum and plasma 200300 |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISO SO (14971:2012;EN ISO 13 SO (18113-1:2011;EN ISO | ance with Directive 98/79/EC Catalogue number Catalogue number t Device K460216D ces except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15211:2003; 18113-2:2011;EN ISO 18113-3:2011; | | ARS-CoV-2Antibody tradeoutletownethod) Control and the second | Serum and plasma 200300 Serum and p |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISC SO 14971:2012 ;EN ISO 1: | ance with Directive 98/79/EC Catalogue number Catalogue number t Device K460216D ces except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15211:2003; 18113-2:2011;EN ISO 18113-3:2011; | | ARS-CoV-2Antibody tradeoutletownethod) Control and the second | Serum and plasma 200300 Serum and p |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISO SO (14971:2012;EN ISO 13 SO (18113-1:2011;EN ISO | ance with Directive 98/79/EC Catalogue number Catalogue number t Device K460216D ces except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15211:2003; 18113-2:2011;EN ISO 18113-3:2011; | | ARS CoV 2Antibody at (Lateral flow method) Control of the second seco | Serum and plasma 20-30 C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi formity assessment route: A licable Standards:EN ISO SO 14971:2012 ;EN ISO 15 SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366; | ance with Directive 98/79/EC Catalogue number Catalogue number t Device K460216D ces except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15211:2003; 18113-2:2011;EN ISO 18113-3:2011; | | ARS CoV 2Antibody at (Lateral flow method) Control of the second seco | Serum and plasma 20-30 C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISC SO 14971:2012 ;EN ISO 1: SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366; the Manufacturer, herewitt ioned above meet/s the p | ance with Directive 98/79/EC Catalogue number t Device K460216D ces except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 8612:2002;EN ISO 17511:2003; 18113-2:2011;EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our pr ovisions of the Directive 98/79/EC of the Er | | ARS-CoV-2Antibody at (Lateral flow method) Control flow method) Control flow method Control flow method Control flow method No. QS6 058008 0029 Certificate Holder: Certification Mark: Scope of Certificate: | Serum and plasma ZC-SUC |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISC SO 14971:2012 ;EN ISO 1: SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366; the Manufacturer, herewitt ioned above meet/s the p | ance with Directive 98/79/EC Catalogue number t Device K460216D tces except Annex II and self-testing devices) nnex III, except Point 6, of Directive 0.13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 17511:2003; 18113-2:2011,EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our pr | | ARS-CoV-2Antibody at (Lateral flow method) Control flow method) Control flow method Control flow method Control flow method No. QS6 058008 0029 Certificate Holder: Certification Mark: Scope of Certificate: | Serum and plasma 2C-30C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISC SO 14971:2012 ;EN ISO 1: SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366; the Manufacturer, herewitt ioned above meet/s the p ament and of the Council o hereby explicitly appoint W | ance with Directive 98/79/EC Catalogue number t Device K460216D ccs except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 8612:2002;EN ISO 15213-1:2003; 18113-2:2011,EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our pr ovisions of the Directive 98/79/EC of the Er n In-Vitro Diagnostic Medical Devices. ellkang Ltd,located at Suite B,29 Harley Street | | ARS-CoV-2Antibody In (Lateral flow method) | Serum and plasma 2C-30C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISO SO 14971:2012 ;EN ISO 13 SO 14971:2012 ;EN ISO 13 SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366; the Manufacturer, herewitt ioned above meet/s the pr anent and of the Council o mereby explicitly appoint W lon W1G 9QR,England,Un | ance with Directive 98/79/EC Catalogue number t Device K460216D ccs except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15223-1:2016; 18113-2:2011,EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our pr ovisions of the Directive 98/79/EC of the En n In-Vitro Diagnostic Medical Devices. ellkang Ltd,located at Suite B,29 Harley Street ited Kingdom to act as our European Authoriss | | ARS-CoV-2Antibody at (Lateral flow method) Caretal and a standard a standard a standard a standard and a standard a standa | Serum and plasma ZC-SUC |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISC SO 14971:2012 ;EN ISO 1: SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366; the Manufacturer, herewitt ioned above meet/s the p ament and of the Council o hereby explicitly appoint W | ance with Directive 98/79/EC Catalogue number t Device K460216D ccs except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15223-1:2016; 18113-2:2011,EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our pr ovisions of the Directive 98/79/EC of the En n In-Vitro Diagnostic Medical Devices. ellkang Ltd,located at Suite B,29 Harley Street ited Kingdom to act as our European Authoriss | | ARS-CoV-2Antibody at (Lateral flow method) Caretal and a standard a standard a standard a standard and a standard a standa | Serum and plasma ZC-30C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISO SO 14971:2012 ;EN ISO 13 SO 14971:2012 ;EN ISO 13 SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366; the Manufacturer, herewitt ioned above meet/s the pr anent and of the Council o mereby explicitly appoint W lon W1G 9QR,England,Un | ance with Directive 98/79/EC Catalogue number t Device K460216D ccs except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15223-1:2016; 18113-2:2011,EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our pr ovisions of the Directive 98/79/EC of the En n In-Vitro Diagnostic Medical Devices. ellkang Ltd,located at Suite B,29 Harley Street ited Kingdom to act as our European Authoriss | | ARS-CoV-2Antibody at (Lateral flow method) Caretal and a standard a standard a standard a standard and a standard a standa | Serum and plasma ZC-30C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tess gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISO SO 14971:2012 ;EN ISO 13 SO 14971:2012 ;EN ISO 13 SO 18113-1:2011;EN ISO 50 SO 23640:2015;EN 62366; the Manufacturer, herewiti ioned above meet/s the pr ament and of the Council o mereby explicitly appoint W lon W1G 9QR,England,Un esentative as defined in the | ance with Directive 98/79/EC Catalogue number t Device K460216D ccs except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15223-1:2016; 18113-2:2011,EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our pr ovisions of the Directive 98/79/EC of the En n In-Vitro Diagnostic Medical Devices. ellkang Ltd,located at Suite B,29 Harley Street ited Kingdom to act as our European Authoriss | | ARS-CoV-2Antibody at (Lateral flow method) Caretal and a standard a standard a standard a standard and a standard a standa | Serum and plasma 2C-30C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISO SO 14971:2012 ;EN ISO 13 SO 14971:2012 ;EN ISO 13 SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366; the Manufacturer, herewitt ioned above meet/s the pr anent and of the Council o mereby explicitly appoint W lon W1G 9QR,England,Un | ance with Directive 98/79/EC Catalogue number t Device K460216D ccs except Annex II and self-testing devices) nnex III,except Point 6,of Directive D 13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15223-1:2016; 18113-2:2011,EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our pr ovisions of the Directive 98/79/EC of the En n In-Vitro Diagnostic Medical Devices. ellkang Ltd,located at Suite B,29 Harley Street ited Kingdom to act as our European Authoriss | | ARS-CoV-2Antibody at (Lateral flow method) Caretal and a standard a standard a standard a standard and a standard a standa | Serum and plasma 2C-30C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tess gory: Other Devices (All devi ormity assessment route: A licable Standards:EN ISO SO 14971:2012 ;EN ISO 13 SO 14971:2012 ;EN ISO 13 SO 18113-1:2011;EN ISO 50 SO 23640:2015;EN 62366; the Manufacturer, herewiti ioned above meet/s the pr ament and of the Council o mereby explicitly appoint W lon W1G 9QR,England,Un esentative as defined in the | ance with Directive 98/79/EC Catalogue number t Device K460216D tces except Annex II and self-testing devices) nnex III, except Point 6, of Directive 0.13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 17511:2003; 18113-2:2011;EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our provisions of the Directive 98/79/EC of the Ear In In-Vitro Diagnostic Medical Devices. ellkang Ltd,located at Suite B,29 Harley Street ited Kingdom to act as our European Authorise aforementioned Directive. Directive | | ARS-CoV-2Antibody at (Lateral flow method) Automatical flow method) Automatical flow method | Serum and plasma 2C-30C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi formity assessment route: A licable Standards:EN ISO SO 14971:2012 ;EN ISO 1: SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366: the Manufacturer, herewiti ioned above meet/s the pr ament and of the Council o hereby explicitly appoint W lon WIG 9QR,England,Un esentative as defined in the Hay 2hett. 2019:35 | ance with Directive 98/79/EC Catalogue number t Device K460216D tces except Annex II and self-testing devices) nnex III, except Point 6, of Directive D13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 15213-2011; 2008. h declare with sole responsibility that our provisions of the Directive 98/79/EC of the En n In-Vitro Diagnostic Medical Devices. ellkang Ltd, located at Suite B,29 Harley Street ited Kingdom to act as our European Authorise aforementioned Directive. | | ARS-CoV-2Antibody at (Lateral flow method) Automation and a constraints CERTIFICATION No. QS6 058008 0029 Certificate Holder: Certification Mark: Scope of Certificate: Standard(s): Regulatory Authority(ies): The Certification Body of TUV SI manufacture listed above has b carteria for the scope of certificate UV SUD America Inc. is an MD DUNS No: Effective Date: Expling Date: | Serum and plasma ZC-30C |
| in accord nufacturer: Product/s 2019-nCOV IgG/IgM Rapid Tes gory: Other Devices (All devi formity assessment route: A licable Standards:EN ISO SO 14971:2012 ;EN ISO 1: SO 18113-1:2011;EN ISO SO 23640:2015;EN 62366: the Manufacturer, herewiti ioned above meet/s the pr ament and of the Council o hereby explicitly appoint W lon WIG 9QR,England,Un esentative as defined in the Hay 2hett. 2019:35 | ance with Directive 98/79/EC Catalogue number t Device K460216D tces except Annex II and self-testing devices) nnex III, except Point 6, of Directive 0.13485:2016;EN ISO 15223-1:2016; 3612:2002;EN ISO 17511:2003; 18113-2:2011;EN ISO 18113-3:2011; 2008. h declare with sole responsibility that our provisions of the Directive 98/79/EC of the Ear In In-Vitro Diagnostic Medical Devices. ellkang Ltd,located at Suite B,29 Harley Street ited Kingdom to act as our European Authorise aforementioned Directive. Directive | | ARS-CoV-2Antibody at (Lateral flow method) Automation and a constraints CERTIFICATION No. QS6 058008 0029 Certificate Holder: Certification Mark: Scope of Certificate: Standard(s): Regulatory Authority(ies): The Certification Body of TUV SI manufacture listed above has b carteria for the scope of certificate UV SUD America Inc. is an MD DUNS No: Effective Date: Expling Date: | Serum and plasma ZC-30C |

